Repurposing Drugs for Global Diseases

Reduced Cost, Diminished Risk, More Opportunity

At Algernon Pharmaceuticals, our capital-efficient drug development and repurposing strategy allows us to advance research programs in our pipeline at a much lower cost and risk than other new chemical entity research programs. Our lead candidates, NP-120 (Ifenprodil) and NP-251 (Repirinast) have not only gone through their pre-clinical phase, but since they are previously approved drugs, they have significant safety history in the patient populations they were developed to treat. While AP-188 (N,N-Dimethyltryptamine, or DMT) has never been approved, there have been several Phase 1 studies conducted confirming its safety as well.

Our Pipeline Programs

Candidate / Indication

Development Stages


Phase 1

Phase 2

Phase 3

Regulatory Review

Inflammatory Disease


Chronic Cough & Idiopathic Pulmonary Fibrosis

Phase 2a Pilot Study Complete
Phase 2b Cough Study Planned - Q4, 2023


Chronic Kidney Disease

Began cGMP Manufacturing - Q1, 2022
Phase 1 Planned - Q3, 2023

Cerebrovascular Disorders



Stroke / Traumatic Brain Injury (TBI)

Began Phase 1- Q1, 2023

A Vertigo Drug for Chronic Cough and IPF

NP-120 (Ifenprodil) is an NMDA receptor antagonist that has been approved in Japan and South Korea to treat vertigo caused by ischemic stroke. We are presently investigating the effectiveness of NP-120 to treat chronic cough and idiopathic pulmonary fibrosis (IPF).

Learn More

An Asthma Drug for Chronic Kidney Disease

NP-251 (Repirinast) was originally an asthma drug developed by Mitsubishi Pharma for the Japanese market and we are investigating its potential to reduce kidney fibrosis and inflammation.


A Psychedelic Drug for Brain Injury

AP-188 (DMT) is a naturally occurring hallucinogenic compound that has been shown to promote neuroplasticity in-vitro, and to reduce the infarct volume and assist in motor function recovery in a rat stroke occlusion study. We are investigating DMT as a potential treatment for stroke and traumatic brain injury (TBI) patients.

Learn More